argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to ...

argenx SE: argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

AM CET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune ...
Clinical Trials Arena on MSN

Argenx to discontinue Phase III trials of thyroid eye disease therapy

The decision comes after the committee recommended halting the studies for futility after reviewing interim data.
Forbes

Citi Double Cash Card Review 2026—Ideal For Everyday Purchases

Kelly-Ann Franklin has spent more than two decades in journalism which has helped her build a wide knowledge base of business and personal finance topics. Her goal with editing is to ensure tough ...